Breaking News
Ad-Free Version. Upgrade your experience. Save up to 40% More details

Bayer seeks glyphosate litigation advice as Elliott reveals stake

Stock MarketsJun 26, 2019 03:13PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
© Reuters. FILE PHOTO: Logo of Bayer AG is pictured at the annual results news conference of the German drugmaker in Leverkusen

FRANKFURT (Reuters) - Chemicals giant Bayer (DE:BAYGN), under pressure from activist shareholders, said on Wednesday it has hired an external lawyer to advise its supervisory board and has set up a committee to help resolve a multi-billion dollar glyphosate litigation issue.

Bayer has seen its share price tumble in the wake of its $63 billion acquisition of Monsanto (NYSE:MON), which brought with it massive legal issues after more than 13,400 plaintiffs alleged the company's glyphosate weedkiller caused cancer.

Bayer, which acquired Monsanto last year, says studies and regulators have deemed glyphosate and Monsanto's Roundup weedkiller safe for human use, but the German company has struggled to contain the reputational and legal fallout.

German Chancellor Angela Merkel said on Wednesday that German farmers would stop using glyphosate eventually, a stance which is at odds with the Leverkusen-based company's view.

Activist shareholder Elliott Associates said it welcomed Bayer's new steps to improve supervision of litigation issues, as it revealed for the first time its holding of Bayer shares.

Bayer said it has hired U.S. lawyer John H. Beisner from Skadden, Arps, Slate Meagher & Flom LLP to advise the Supervisory Board on matters related to the glyphosate litigations, including trial tactics and mediation.

"His appointment is intended to add fresh and independent perspectives to the advice given to the Board of Management," Bayer said in a statement.

"We are convinced that with his expertise, John H. Beisner will provide very valuable and concrete advice on the ongoing litigation as well as the mediation," Bayer's Chairman Werner Wenning, said in the statement.

Bayer also said a new Supervisory Board committee, comprised of eight supervisory board members, will consult with the Board of Management and make recommendations on litigation strategy.

The company appears to have changed its approach to litigation, from taking a "we will prevail, we will fight to the end" attitude to seeking a settlement more quickly as a way to reassure investors and employees, a person familiar with the discussion told Reuters on Wednesday.

Elliott Associates revealed that it holds Bayer shares and financial instruments equivalent to 1.1 billion euros ($1.3 billion) worth of Bayer stock. Bayer's market value is 52.2 billion euros.

It is the first time that Elliott has acknowledged holding a significant stake in the German company. Reuters last year reported that Elliott had amassed a stake of under 3%, citing people familiar with the matter.

Elliott has a stake equivalent to 2.1% of Bayer shares, a source familiar with the matter said on Wednesday.

"Elliott welcomes these steps, and is confident that today’s statement marks a step change in Bayer’s approach to addressing the legal challenges currently facing the company," Elliott said in a separate statement.

Elliott said it believes that the creation of the special committee will provide a new level of oversight and a fresh perspective to a litigation strategy, which it said needs a radical overhaul.

Elliott also said Bayer could do more to maximize long-term value for all its stakeholders, saying the company had an opportunity to unlock more than 30 billion euros in value.

"Elliott looks forward to the company building upon today's announcement, and making a credible commitment to the exploration of long-term value creative levers beyond the immediate litigation and governance enhancements," it said.

Elliott wants Bayer to resolve its litigation issues as an immediate priority and is not pushing the company to pursue deeper structural changes right away, the source said.

Bayer seeks glyphosate litigation advice as Elliott reveals stake

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at’s discretion.

Write your thoughts here
Are you sure you want to delete this chart?
Post also to:
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Are you sure you want to delete this chart?
Replace the attached chart with a new chart ?
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
Sign up with Email